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15 Abstract Retinoprotective effects of pituitary adenylate cy-
16 clase activating polypeptide (PACAP) are well-known and
17 have been demonstrated in various pathological conditions,
18 such as diabetic retinopathy, excitotoxic retinal injury, UV
19 light-induced degeneration, and ischemic retinal lesion. The
20 neuronal degeneration observed in the different retinal layers
21 under the above pathological conditions can be successfully
22 decreased by PACAP; however, whether this morphological
23 improvement is also reflected in functional amelioration re-
24 mains unknown. Therefore, our purpose was to investigate the
25 protective effect of PACAP on the rat retina after bilateral
26 common carotid artery occlusion (BCCAO) with electroreti-
27 nography (ERG) to parallel the functional data with the pre-
28 vious morphological and neurochemical observations.
29 Control eyes received saline treatment while PACAP was
30 injected into the vitreous space of the other eye immediately
31 after the induction of ischemia. Retinal damage and protective
32effects of PACAP were quantified by the changes in the wave
33forms and amplitudes. On postoperative days 2 and 14, sev-
34eral parameters were assessed with special attention to the
35changes of b wave. The results confirm that the previously
36described morphological protection induced by PACAP treat-
37ment is reflected in functional improvement in ischemic reti-
38nal lesions.
39Keywords Rat . Electroretinography . BCCAO . PACAP .
40Functional retinoprotection
41Introduction
42Pituitary adenylate cyclase activating polypeptide (PACAP) is
43a neuropeptide that belongs to the VIP/glucagon/secretin neu-
44ropeptide family (Vaudry et al. 2009). PACAP has, among
45others, very potent neuroprotective effects that have been
46proven in several in vitro and in vivo models of neuronal
47injuries (Shioda et al. 2006; Somogyvari-Vigh and Reglodi
482004; Vaudry et al. 2000). Numerous data support the protec-
49tive effects of PACAP in ischemic lesions. Among others,
50PACAP treatment results in smaller infarct size in focal cere-
51bral ischemia, it leads to less extensive hippocampal damage
52in global cerebral ischemia, and it decreases postischemic
53endothelial dysfunction (Lenti et al. 2009; Ohtaki et al.
542008; Reglodi et al. 2002). Mice deficient in endogenous
55PACAP have larger infarct size in models of stroke (Chen
56et al. 2006; Ohtaki et al. 2006). PACAP is also protective in
57ischemic retinal lesions (Atlasz et al. 2010a), in addition to the
58various other types of retinopathies in animal models, such as
59diabetic retinopathy, excitotoxic retinal injury, UV light-
60induced degeneration (Nakamachi et al. 2012; Szabadfi et al.
612010, 2012a). The lack of endogenous PACAP causes a more
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62 severe ischemic retinal lesion, which can be counteracted by
63 exogenous PACAP treatment (Szabadfi et al. 2012b).
64 Whether the morphological ameliorative effects are also
65 reflected in functional improvement is an essential question
66 for determining the efficacy of PACAP. Electroretinography
67 (ERG) is a suitable method for making such assessments. An
68 entire record of ERG consists of a negative wave (a wave)
69 followed by a positive wave (b wave) with two to five oscil-
70 latory potentials on the rising slope (Imai et al. 1990). There is
71 a largely variable c wave, the origin of which is attributed to
72 the pigment epithelium or the glial (Müller) cells of the retina
73 (Noell 1963; Gouras 1970; Perlman 2009). The amplitude of
74 each component of the ERG varies from animal to animal,
75 whereas they are very stable within the same animal (Perlman
76 1995; Imai et al. 1990). ERG is useful for the detection of
77 early-stage retinal dysfunction (Gouras 1970; Perlman 2009;
78 Shahar et al. 2012). The gross physiological response of the
79 retina to ischemia is commonly measured using the ERG,
80 whose b wave component has attributes from the interaction
81 between photoreceptors and ON bipolar cells (Gurevich and
82 Slaughter 1993; Osborne et al. 2004). Recordings of ERG
83 showed reduction of the b wave during the bilateral common
84 carotid artery occlusion (BCCAO) (Block et al. 1992; Barnett
85 and Osborne 1995; Osborne et al. 1999) indicating an effect at
86 the level of the photoreceptors, bipolar cells, and Müller cells.
87 Indeed, earlier we have described by ERG, which measures
88 electric potentials of the retina indicative of visual function,
89 that PACAP improves the functional outcome after
90 excitotoxic retinal lesions (Varga et al. 2011).
91 Retinal ischemia/hypoperfusion is one of the leading
92 causes of retinal degeneration and blindness, which can be
93 modelled by permanent BCCAO in rats. A severe ischemic
94 insult affects retinal ganglion cells first; additional damage to
95 most of the inner retina develops slower and finally photore-
96 ceptors can also be affected (Hughes 1991; Osborne et al.
97 2004). Blood flow in the retina is severely reduced after
98 BCCAO (Gurevich and Slaughter 1993; Osborne et al.
99 2004). Although numerous data prove that PACAP has mul-
100 tiple retinoprotective effects in excitotoxic retinal degenera-
101 tion, it is still not known whether PACAP treatment-induced
102 morphological and neurochemical protection in ischemia cor-
103 relate with functional amelioration. Therefore, our purpose
104 was to investigate the protective effect of PACAP on the rat
105 retina after BCCAOwith ERG and parallel the functional data
106 with the previously described morphological and neurochem-
107 ical results (Atlasz et al. 2007, 2010b).
108 Materials and Methods
109 In order to induce hypoperfusion of the retina, BCCAO was
110 carried out on Wistar rats (n=8; 3 months of age, weighing
111 350 g). Carotid arteries on both sides were permanently
112ligated under isoflurane anesthesia, according to previous
113descriptions (Atlasz et al. 2007). The operation was immedi-
114ately followed by intravitreal PACAP treatment (100 pmol in
1155 μl vehicle/eye) into the right eye, while saline was injected
116into the other eye as we have previously described.
117Experimental procedures were carried out in accordance with
118approved protocols (University of Pecs; no: BA02/2000-
11915024/2011).
120ERG measurements were performed to assess retinal func-
121tion in each group, after an overnight dark adaption. The
122animals were anesthetized by intraperitoneal injection of ke-
123tamine 5 % (w/v, Calypsol, Richter Gedeon, Hungary, 90 mg/
124BW kg) and xylazine 20 % (w/v, Sedaxylan, Dechra,
125Netherlands, 10 mg/ kg) during the electrophysiological
126measurements (Sharp and La Regina 1998). The pupils
127were dilated with 0.5 % cyclopentolate (w/v, Humapent-
128Teva, Hungary). Oxybuprocaine 0.4 % eye drops
129(Humacain-Teva, Hungary) were used for the topical
130anesthesia. Flash ERG was recorded before BCCAO as
131nontreated controls and on postoperative days 2, 6, 10,
132and 14 in each group.
133ERG potentials arise in the retina after light stimulation and
134they are detectable all around the eye, being the largest in the
135center of the cornea (Gouras 1970; Perlman 1995). ERGs
136were recorded by surface electrodes from the center of the
137cornea with the negative electrode placed under the skin of
138the cheek and the ground electrode stuck under the skin
139of the neck. All procedures were performed under a dim
140red LED light (632 nm; Zhang et al. 2013). The re-
141sponses to light flashes (5.0 cd/m2, 0.25 Hz, 503 nm
142green LED light) were pre-amplified, amplified (2,000×,
143Bioamp SbA4-V6, Supertech, Hungary), and recorded
144with an A/D converter (Ratsoft-Solar Electronic;
145Jacobs et al. 2001; Szabo-Salfay et al. 2001).
146Responses (n=150) were averaged with the software of
147the A/D converter to draw the graph of each measure-
148ment. The values of the selected parameters were ana-
149lyzed by two-way ANOVA with Bonferroni post hoc
150analysis (p<0.05; p<0.01; p<0.001).
151Histological examination was carried out to confirm
152the severity of the retinal lesions and correlate function-
153al changes with morphological alterations induced by
154ischemia and PACAP treatment. After the termination
155of the ERG measurements, rats were decapitated under
156isoflurane anesthesia and eyes were immediately dissect-
157ed in ice-cold phosphate buffered saline (PBS; VWR
158International, Hungary) and fixed in 4 % paraformalde-
159hyde (PFA; Merck, Hungary). Retina histology was
160performed on Durcupan ACM resin (Sigma, Hungary)
161embedded tissues. Sections were cut at 2 μm, stained
162with toluidine blue (Sigma), and examined in a Nikon
163Eclipse 80i microscope as we have previously described
164(Atlasz et al. 2007).
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165 Results
166 We investigated the possible effects of PACAP treatment in
167 BCCAO-induced ischemic retinal degeneration on neuronal
168 cell activity by recording ERGs at various time points before
169 (control measurements) and 2, 6, 10, and 14 days after the
170 induction of ischemia. Representative ERG recordings of the
171 untreated and PACAP-treated eyes are shown in Fig. 1.
172 Control average ERG waveforms were similar in both left
173 and right eyes (Fig. 1a, b). Our results show that BCCAO
174 caused a severe functional damage reflecting the previously
175 described alteration of the histological structure (Atlasz et al.
176 2007). BCCAO-induced functional retinal degeneration was
177 already observed on postoperative days 2 and lasted through-
178 out the entire observation period. Intravitreal injection of
179 PACAP immediately after BCCAO resulted in a more
180 retained retinal function as assessed by average ERG wave-
181 forms compared to the BCCAO-operated groups on both
182 postoperative 2nd and 14th days (Fig. 1). The same tendencies
183 could be observed on postoperative day 6 and 10 (data not
184 shown). Average amplitudes of waves decreased with the
185 duration of ischemia in BCCAO eyes (Figs. 1 and 2).
186 Differences were found in the average amplitudes of the a
187 waves and b waves between control and vehicle-treated
188BCCAO eyes, but no differences could be observed in the
189case of c wave on postoperative day 14 (Fig. 2a). ERGs of
190PACAP-treated ischemic eyes were similar to the intact con-
191trols in contrast to the ERGs of saline-treated BCCAO retinas.
192PACAP treatment significantly counteracted the ischemia-
193induced alterations in the amplitudes of both the a and b
194waves of the ERG on postoperative day 14 (Fig. 2a).
195Amplitudes of the b wave decreased in BCCAO (33 % of
196controls). Significant difference could be detected between
197BCCAO and PACAP-treated BCCAO groups on postopera-
198tive day 14 (53 % of control; Fig. 2b). The same tendency
199could be observed on postoperative day 2 in BCCAO- and
200BCCAO + PACAP-treated groups in the b wave amplitudes
201(Fig. 2b). A slight but not significant decrease in the b wave/a
202wave amplitude ratio (b/a) was observed in the BCCAO and
203PACAP-treated BCCAO retinas (Fig. 2c).
204The latency of b/a waves was significantly decreased in
205both BCCAO- and PACAP-treated BCCAO groups compared
206to their controls, but no differences could be observed between
207the treated and untreated ischemic groups (Fig. 3a). The elapse
208time of the five major oscillatory potentials (OPs) was reduced
209in the BCCAO ischemic group, but PACAP treatment led to
210significant protection (Fig. 3b). The morphological parame-
211ters are in accordance with our previous observation that
212PACAP treatment ameliorated the BCCAO-induced retinal
213degeneration (Atlasz et al. 2007, 2010a, b; Fig. 4).
214Discussion
215The present results show that the morphological protection
216exerted by PACAP in ischemic retinal lesion is accompanied
217by functional amelioration, as reflected by electrical activity.
218We have previously described that PACAP exerts morpholog-
219ical and neurochemical protection in BCCAO-induced retinal
220degeneration (Atlasz et al. 2007, 2010b). However, functional
221outcome measures, such as ERG, were missing.
222Electroretinogram displays a composite retinal electric activity
223which depends upon different cells, extending from the pig-
224ment epithelium to the innermost retinal layers (Noell 1953;
225Brown 1968), allowing differential participation of cells with-
226in different layers (Grozdanic et al. 2003; Vilela et al. 1998;
227Arden et al. 1982). This method is attractive in assessing
228retinal neurodegeneration because it is not invasive and can
229thus be used in longitudinal assessments. The ERGs for all
230control eyes in our present study were well within the range of
231previously published normative data (Bui and Fortune 2004;
232Szabo-Salfay et al. 2001). The results of this study demon-
233strate that the b wave is the most sensitive detectable ERG
234parameter of functional abnormalities in this rat model of
235BCCAO-induced retinal ischemia. Our observations suggest
236that BCCAO and PACAP treatment also led to changes in
237neuronal cell activity of the retina. The main functional
Fig. 1 Representative average ERG recordings of BCCAO (a) and
PACAP-treated BCCAO (b) groups on postoperative days 2 and 14.
The BCCAO-induced retinal degeneration was first observed in the
alteration of the amplitudes of the waves on postoperative day 2 (a).
Partial recovery of the ischemia-induced changes in the PACAP-treated
animals was evident by postoperative day 14 (b). Control measurements
were made before BCCAO from the same animals
J Mol Neurosci
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238 protective effects of PACAP were showed by the alteration of
239 the b wave amplitudes.
240 Although retinal ganglion cells are the most vulnerable to
241 severe ischemia of the retina (Osborne et al. 2004) and their
242 damage was found most prominent after BCCAO (Yamamoto
243 et al. 2006), it has been shown that 2 weeks after the operation,
244 other cellular layers are also seriously degenerated (Atlasz
245 et al. 2007; Farkas et al. 2007). Therefore, deterioration of
246 the ERG can be expected. Former studies have identified the
247 OPs of the flash-elicited ERG b wave as sensitive indices of
248 abnormalities within the retinal circulation (Kergoat and
249Lovasik 1990). The OPs are quantitative and objective index
250for dysfunction and manifested earliest not only in ischemic
251conditions but also in diabetic retinopathy (Yonemura et al.
2521962; Galloway et al. 1971), which also involves worsened
253circulation and production of reactive oxygen species
254(Fernandes et al. 2011).
255Compared to nonischemic (control) values, the ERG a and
256b wave amplitudes were strongly reduced after the BCCAO
257operation. PACAP treatment alleviated the functional conse-
258quences of BCCAO-induced ischemia. In our previous stud-
259ies, the beneficial effects of PACAP were observed at
Fig. 2 Comparative analysis of
the average amplitudes of
different waves (a), the amplitude
ratio of b/a waves (c) on
postoperative day 14, and the
alteration of amplitudes of b
waves on postoperative days 2
and 14 (b). Ischemia induced
significant alterations in the
amplitudes of a waves and b
waves compared to the controls.
PACAP treatment reduced the
deterioration and patterns were
similar to the control group. No
significant differences could be
registered in the amplitude of c
wave between the three groups (a,
**p<0.01; ***p<0.001 vs.
control; #p<0.05 vs. BCCAO).
The changes of the amplitudes of
different waves were recognized
on postoperative days 2 and 14.
Significant alteration could be
observed in the amplitudes of b
waves between the control,
ischemic, and PACAP-treated
BCCAO groups on day 14 (b,
*p<0.05; **p<0.01 vs. control).
No significant differences could
be observed in the amplitude ratio
of b/a waves between the control,
ischemic and the PACAP-treated
ischemic group (C, *p<0.05 vs.
control; #p<0.05 vs. BCCAO).
n=8 in each group
J Mol Neurosci
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Fig. 3 Comparative analysis of
time latency ratio of b/awaves (a)
and differences in elapse time of
OPs (b) between the three groups
on postoperative day 14.
Significant differences could be
observed in the time latency ratios
of b/a waves between the
ischemic and the PACAP-treated
ischemic groups. However, there
are no significant differences
between the BCCAO- and
PACAP-treated BCCAO groups
(a, ***p<0.001 vs. control).
Significant differences could be
observed in the elapse time of
OPs between control and
BCCAO animals, but no
significant differences were seen
between the control and PACAP-
treated BCCAO groups. PACAP
treatment led to significant
retention of the elapse time ofOPs
(b,*p<0.05 vs. control; #p<0.05
vs. BCCAO). n=8 in each group
Fig. 4 Representative sections of control (a), BCCAO (b), and PACAP-
treated BCCAO (c) retinas stained with toluidine blue. Morphological
differences were found between the examined groups; PACAP treatment
could ameliorate the ischemia-induced retinal degeneration. Scale bar:
20 μm. Abbreviations: PL photoreceptor layer, ONL outer nuclear layer,
OPL outer plexiform layer, INL inner nuclear layer, IPL inner plexiform
layer, GCL ganglion cell layer
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260 histological and neurochemical levels (Atlasz et al. 2007,
261 2010b; Szabo et al. 2012). The present results indicate the
262 PACAP treatment induced a significant recovery of the wave-
263 form and amplitudes of a wave and b wave as seen in ERG.
264 PACAP treatment did not completely prevent retinal dysfunc-
265 tion; however, the ERG recovery was a sustained effect noted
266 as early as 2 days after BCCAO.
267 There are two further interesting results in the ERG record-
268 ings. One is that after BCCAO, the a wave amplitudes in-
269 crease slightly, possibly reflecting a relatively late and low
270 level of photoreceptor damage and the lack of intraretinal
271 negative feedback. This is supported by the fact that the
272 thickness of the outer nuclear layer did not change as much
273 as the inner retinal layers and the photoreceptors look rela-
274 tively healthy in the histological preparations. The second
275 observation is that the b/a wave latency ratio did not improve
276 significantly after PACAP treatment. A possible explanation
277 for that is that the time after BCCAOwas not sufficient for the
278 degenerations to reach the photoreceptors retrogradely. Our
279 present results confirm our earlier findings in excitotoxic
280 retinal damage, where PACAP treatment led to functional
281 amelioration parallel with protection reflected in morpholog-
282 ical structure (Varga et al. 2011).
283 In conclusion, the results reported in the present study
284 demonstrate a functional protective effect of PACAP against
285 retinal ischemic injury caused by BCCAO. Since this is the
286 second metabolically induced retinal degeneration model
287 where we can demonstrate such protection, data are convinc-
288 ing that morphological and neurochemical protection go par-
289 allel with functional protection.
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